Listed

CVS HEALTH Corp: Form 10-Q for the period ended Sep 30, 2014

Filed with the SEC on Nov 4, 2014 and accepted by EDGAR at Nov 4, 2014, 16:03 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-07-01 to 2014-09-30$35.02bnus-gaap:Revenues
Revenue9 months2014-01-01 to 2014-09-30$102.31bnus-gaap:Revenues
Cost of revenue3 months2014-07-01 to 2014-09-30$28.55bnus-gaap:CostOfRevenue
Cost of revenue9 months2014-01-01 to 2014-09-30$83.58bnus-gaap:CostOfRevenue
Gross profit3 months2014-07-01 to 2014-09-30$6.47bnus-gaap:GrossProfit
Gross profit9 months2014-01-01 to 2014-09-30$18.73bnus-gaap:GrossProfit
Operating income3 months2014-07-01 to 2014-09-30$2.25bnus-gaap:OperatingIncomeLoss
Operating income9 months2014-01-01 to 2014-09-30$6.48bnus-gaap:OperatingIncomeLoss
Interest expense3 months2014-07-01 to 2014-09-30$158.0mus-gaap:InterestExpense
Interest expense9 months2014-01-01 to 2014-09-30$480.0mus-gaap:InterestExpense
Income tax3 months2014-07-01 to 2014-09-30$624.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2014-01-01 to 2014-09-30$2.17bnus-gaap:IncomeTaxExpenseBenefit
Net income3 months2014-07-01 to 2014-09-30$948.0mus-gaap:ProfitLoss
Net income9 months2014-01-01 to 2014-09-30$3.32bnus-gaap:ProfitLoss
Diluted EPS3 months2014-07-01 to 2014-09-30$0.81us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2014-01-01 to 2014-09-30$2.82us-gaap:EarningsPerShareDiluted
Basic EPS3 months2014-07-01 to 2014-09-30$0.82us-gaap:EarningsPerShareBasic
Basic EPS9 months2014-01-01 to 2014-09-30$2.84us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2014-07-01 to 2014-09-301,164,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2014-01-01 to 2014-09-301,175,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2014-01-01 to 2014-09-30$4.71bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2014-01-01 to 2014-09-30$1.44bnus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2014-01-01 to 2014-09-30$971.0mus-gaap:PaymentsOfDividends
Share repurchases9 months2014-01-01 to 2014-09-30$2.80bnus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2014-09-30$1.13bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-09-30$25.34bnus-gaap:AssetsCurrent
Total assetsAt period end2014-09-30$73.58bnus-gaap:Assets
Current liabilitiesAt period end2014-09-30$18.21bnus-gaap:LiabilitiesCurrent
Short-term borrowingsAt period end2014-09-30$775.0mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2014-09-30$38.10bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000064803-14-000036. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.